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Abstract
Background: Collagen proportionate area (CPA) measurement is a technique that
quantifies fibrous tissue in liver biopsies by measuring the amount of collagen depo-
sition as a proportion of the total biopsy area. CPA predicts clinical outcomes in
patients with HCV and can sub‐classify cirrhosis.
Aim: To test the ability of CPA to quantify fibrosis and predict clinical outcomes in
patients with NAFLD.
Methods: We assessed consecutive patients with biopsy‐proven NAFLD from three
European centres. Clinical and laboratory data were collected at baseline and at the
time of the last clinical follow‐up or death. CPA was performed at two different
objective magnifications, whole biopsy macro and ×4 objective magnification, named
standard (SM) and high (HM) magnification respectively. The correlation between
CPA and liver stiffness was assessed in a sub‐group of patients.
Results: Of 437 patients, 32 (7.3%) decompensated and/or died from liver‐related
causes during a median follow‐up of 103 months. CPA correlated with liver stiffness
and liver fibrosis stage across the whole spectrum of fibrosis. HM CPA was signifi-
cantly higher than SM CPA in stages F0‐F3 but similar in cirrhosis, reflecting a
higher ability to capture pericellular/perisinusoidal fibrosis at early stages. Age at
baseline (HR: 1.04, 95% CI: 1.01‐1.08), HM CPA (HR: 1.04 per 1% increase, 95% CI:
1.01‐1.08) and presence of advanced fibrosis (HR: 15.4, 95% CI: 5.02‐47.84) were
independent predictors of liver‐related clinical outcomes at standard and competing
risk multivariate Cox‐regression analysis.
Conclusions: CPA accurately measures fibrosis and is an independent predictor of
clinical outcomes in NAFLD; hence it merits further evaluation as a surrogate end-
point in clinical trials.
The Handling Editor for this article was Professor Stephen Harrison, and it was accepted
for publication after full peer‐review.
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1 | INTRODUCTION
Non‐alcoholic fatty liver disease (NAFLD) is the hepatic manifesta-
tion of the metabolic syndrome affecting 30% of the population in
industrialised countries.1,2 NAFLD is a complex pathological entity
that develops from multiple factors acting synergistically in geneti-
cally and/or epigenetically predisposed individuals.3,4
Despite its high prevalence, only a proportion of subjects with
NAFLD develop non‐alcoholic steatohepatitis (NASH) with potential
progression to fibrosis and cirrhosis.1,5 Therefore, it is important to
stratify patients according to their risk of progression in order to tai-
lor the need for interventions and dedicated specialist follow‐up.6
The gold standard to differentiate NAFLD from NASH and accurately
stage fibrosis is a liver biopsy, despite the development of several
non‐invasive fibrosis assessment tests.7 This is because the currently
available non‐invasive techniques have a satisfactory accuracy for the
detection of advanced fibrosis but not for lower fibrosis stages.8
Our group developed the collagen proportionate area (CPA) mea-
surement as a technique to quantify fibrous tissue in liver biopsies by
measuring the amount of collagen deposition as a proportion of the
total biopsy area. CPA has been validated against hepatic venous pres-
sure gradient (HVPG) measurement and clinical outcomes mainly in
patients with chronic hepatitis C. Along these lines, CPA can sub‐clas-
sify cirrhosis and predict decompensation independently of the model
for end‐stage liver disease (MELD) score.9–14 However, NASH, particu-
larly in the early stages of the disease, is characterised by pericellular
and perisinusoidal fibrosis in the centrilobular area, which is a pattern
of fibrosis progression different from the periportal localisation typical
of chronic viral hepatitis. Therefore, it is not yet established whether
CPA at the standard magnification employed and validated for chronic
viral hepatitis, can measure collagen with sufficient accuracy in the
early stages of NAFLD‐related fibrosis. Moreover, there are no studies
on the utility of CPA in relation to clinical outcomes in NAFLD.
This study had therefore two aims: firstly, to test the optimal CPA
magnification to identify liver fibrosis in NAFLD patients; secondly, to
assess the association of CPA with clinical outcomes, namely hepatic
decompensation and/or liver‐related mortality, in a cohort of patients
with biopsy‐proven NAFLD and longitudinal follow‐up.
2 | MATERIALS AND METHODS
This was a multicenter, retrospective study including patients from
three centres in the United Kingdom, Sweden and Greece. All cases
with biopsy‐proven NAFLD with available clinical and laboratory data
who were seen at least once after the baseline liver biopsy during a
period of 30 years were selected by a systematic search of the hos-
pital histology registers.
Patients with alcohol overconsumption (defined as alcohol intake
>20 g/d in women and >30 g/d in men, as confirmed by patient clin-
ical history), secondary causes of steatosis (such as steatogenic medi-
cation or previous gastro‐intestinal by‐pass) or coexistent liver
disease were excluded.
Clinical information including body mass index (BMI), presence of
hypertension, diabetes mellitus or impaired fasting glucose, dyslipi-
demia (diagnosed according to the latest Adult Treatment Panel III
criteria),15 cardiovascular disease and previous cardiovascular events
were obtained from clinical documentation recorded at the time of
liver biopsy or within a range of 6 months. Routine laboratory
parameters were collected.
The development of hepatic decompensation (defined as the
development of either ascites, variceal bleeding, hepatic
encephalopathy or clinical non‐obstructive jaundice) and cardiovascu-
lar events during the follow‐up period, as well as the survival status
of each patient were recorded at the end of the data collection
(June 30, 2016), through the clinical notes, general practitioner
enquiries or the national health system‐integrated hospital register.
We further evaluated a separate cohort of consecutive contem-
porary patients with biopsy‐proven NAFLD and liver stiffness mea-
surements by transient elastography (FibroScan®), performed within
6 months of the liver biopsy, in order to test the correlation of CPA
with liver stiffness. The study was approved by the ethical review
board of each participating institution (REC reference number 07/
Q0501/50).
2.1 | Histological assessment
Liver biopsy samples were formalin‐fixed, paraffin‐embedded and
routinely stained with hematoxylin and eosin (H&E), periodic acid–
Schiff (PAS) stain with diastase digestion (DPAS), orcein, Victoria
Blue and Perls’ Prussian Blue. Another section of tissue was stained
with picro‐Sirius red for collagen quantification and determination of
CPA by digital image analysis.
Liver biopsy samples were centrally reviewed by an expert
histopathologist (TVL, Royal Free Hospital) blinded to the clinical
data of the patients. NASH was diagnosed based on a compatible
morphological pattern of injury and the combination of steatosis,
lobular inflammation and hepatocyte ballooning. The NAS score was
calculated according to the NASH CRN classification.16 Liver fibrosis
was staged on a 5‐point scale, with 0 for absence of fibrosis, stage 1
for zone 3 perisinusoidal/perivenular fibrosis, stage 2 for zone 3 and
periportal fibrosis, stage 3 for septal/bridging fibrosis and stage 4 for
cirrhosis.17 Significant and advanced fibrosis were defined as Brunt
stage ≥F2, and ≥F3 respectively.
2.2 | CPA analysis
CPA was measured as described previously.12 For the purpose of
this study, CPA was measured at different objective magnifications
(whole biopsy macro and ×4 and ×10 objective magnifications).
In summary, whole biopsy images of liver sections stained with
picro‐Sirius red were captured with a Canon Powershot A640 digi-
tal camera attached to a close‐up copy‐stand with non‐flicker
backlighting.
High power (×4 and ×10) image capture was performed using a
microscope and Zeiss Axiocam ICc5 (see Supplementary Material for
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more details). For the high‐power magnification, the difference
between ×4 and ×10 magnification was evaluated in order to choose
the best feasible technique (a balance between resolution vs. effi-
ciency). Digital image analysis used a visual basic script for Zeiss
Axiovision (version 4.8.2.) in which binary segmentation of RGB col-
our channels was used to distinguish liver tissue from collagen. An
editing step was included and confounding artefacts such as major
blood vessels and liver capsule were manually edited from analysis.
The collagen proportionate area (CPA) was calculated as the area
occupied by the collagen as a proportion of the area of the whole
parenchyma and expressed as a percentage.
Initially, we compared ×4 and ×10 CPA measurement on 10 dif-
ferent biopsy slides: since the calculated intra‐class correlation coef-
ficient was high (0.98) we used the ×4 magnification CPA for
simplicity. The whole biopsy macro and ×4 objective magnification
are hereafter termed as standard (SM) and high magnification (HM)
CPA.
The procedure was performed by one of the authors (EB) and
inter‐observer variability was assessed using a separate training
group of 20 slides of patients with cirrhosis, with a different obser-
ver (AH) unaware of EB’s assessment: the concordance was excellent
(k = 0.912) with median CPA difference between observers of 2%.
2.3 | Statistical analysis
Normal distribution was tested before statistical analysis. Continuous
descriptive data are presented as mean and standard deviation when
the assumption of normality was met or otherwise as median and
interquartile range (IQR). Categorical variables were analysed using the
chi‐square test or Fisher's exact test when appropriate. Between‐
group comparisons of continuous variables were performed using the
Student's t test or ANOVA tests for normally distributed variables and
the Mann‐Whitney U or Kruskal‐Wallis tests when the assumption of
normality was not met. The Wilcoxon test was used to compare SM
and HM CPA. The Pearson's correlation test was used to determine
correlation between CPA measurement and liver stiffness and the
Steiger's Z‐test for dependent variables was used to compare correla-
tion coefficients for SM and HM CPA. Cox‐regression (univariate and
multivariate) analysis was used to determine predictors of clinical out-
comes (composite outcome of hepatic decompensation and/or liver‐re-
lated mortality). Competing risk Cox regression analysis, with nonliver
related deaths considered as a competing risk, was also performed. A
backward stepwise procedure was used for Cox models. Receiver‐op-
erating characteristics (ROC) curve analysis was used to define optimal
SM and HM CPA cut‐offs for different stages of fibrosis and for pre-
diction of liver‐related outcomes. A two‐sided p‐value <0.05 was con-
sidered significant.
All analyses were performed using SPSS (version 22.0, IBM, New
York, NY) or MedCalc for Windows (version 14.8.1, MedCalc Soft-
ware, Ostend, Belgium) except from the competing risk analyses,
which were performed using Stata (version 12.1, Statacorp, College
Station, TX).
3 | RESULTS
3.1 | Baseline characteristics
Table 1 shows the baseline clinical, biochemical and histological data of
the 437 patients with NAFLD included in the study, grouped according
to the recruiting centre. The mean age was 51 ± 13 years, mean BMI
was 30.2 kg/m2, 40% of patients were females and 74% were of Cau-
casian ethnicity. A history of type 2 diabetes and hypertension was
prevalent in 38.2% and 53% of patients respectively, while 60.2% were
dyslipidemic. Furthermore, 46 (10.5%) patients already had a cardiovas-
cular event or were affected by cardiovascular disease (mostly ischae-
mic heart disease and arrhythmias) at baseline. Twenty percent of
patients were already on statins, either for treatment of dyslipidemia or
for secondary prevention of cardiovascular disease.
Histology review showed that the median biopsy length was
19 mm (range 4‐58 mm) with 0.5%, 7.2%, 54% and 38% of patients
having biopsy lengths of <5 mm, 5‐10 mm, 11‐20 mm and >20 mm
respectively. Absence of fibrosis (F0) was found in 233 (53%), mild
fibrosis (F1) in 95 (22%), moderate fibrosis (F2) in 37 (8%), severe
fibrosis (F3) in 34 (8%) and cirrhosis (F4) in 38 (9%) patients, respec-
tively. NASH was present in 170 (39%) patients.
3.2 | Clinical outcomes
In total, 32 patients (7.3%) had at least one episode of hepatic
decompensation and/or died of liver‐related causes (18 in the British
cohort, two in the Greek cohort, and 12 in the Swedish cohort). Of
these, 8 (25%) had a fibrosis stage of <F3 according to the Brunt
system at the time of liver biopsy (2 had F0, 3 had F1, 3 had F2).
Twenty‐seven patients (6.2%) had at least one episode of hepatic
decompensation after a median of 58 (IQR: 81, range: 1‐250)
months from their baseline liver biopsy: one patient became jaun-
diced, 16 developed ascites, three had variceal bleeding, three were
hospitalised for hepatic encephalopathy and three developed liver
failure, of which two underwent liver transplantation. One patient
decompensated twice, developing ascites and variceal haemorrhage
respectively. Five patients had multiple decompensating events on a
single admission and subsequently died.
Seventy‐one patients (16.2%) developed a cardiovascular compli-
cation, with a total of 117 events, mainly ischaemic events (n = 34),
arrhythmias (n = 24), congestive heart failure (n = 19) and stroke
(n = 18).
Fifty‐six patients (12.8%) died after a median follow‐up of 103 (IQR:
85, range: 1‐298) months and the larger proportion of events was repre-
sented by liver‐related mortality (n = 16), cardiovascular events (n = 15)
and nonHCC malignancies (n = 14). Of the 16 patients who died due to
liver‐related events, 11 had previously developed at least one episode
of clinical hepatic decompensation during the follow‐up.
3.3 | CPA values and fibrosis stages
CPA values, both at SM and HM, significantly increased according to
incremental stages of liver fibrosis. HM was significantly higher than
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SM CPA in patients who had F2 fibrosis or lower (Table 2): the median
CPA value for patients with F0‐F2 was 4.7% if measured at SM and
6.9% if measured at HM (P < 0.0001), representing a more accurate
measurement of the finer peri‐cellular component of liver fibrosis. For
advanced fibrosis (≥F3) and cirrhosis, the difference between SM and
HM values was less pronounced, with a median CPA value of 10.7%
and 11.2% for advanced fibrosis (P = 0.002) and of 21.3% and 23% for
cirrhosis (P = 0.06) at SM and HM respectively. An example of the dif-
ference in CPA measurements between SM and HM is shown in Fig-
ure 1. We also demonstrated that the difference between SM and HM
CPA is due to more accurate measurement of peri‐sinusoidal fibrosis
using HM (Supplementary material Data S1).
We further explored optimal CPA cut‐offs for individual fibrosis
stages (Table 2, Supplementary material Data S1): presence of any
degree of fibrosis (≥F1), significant fibrosis (≥F2), advanced fibrosis
(≥F3) and cirrhosis were predicted by a HM CPA >6.8%, >8.6%,
>10.4% and >13.6% respectively. We also determined the SM CPA
cut‐offs for fibrosis (Table 2, Supplementary material Data S1).
Importantly, CPA measurements were not influenced by biopsy
length (Supplementary Table S3) or steatosis grade except in the
absence of fibrosis (Supplementary Tables S4). The accuracy of
assigning a specific histological stage using CPA was lower than bin-
ary classification (Supplementary Table S5).
Finally, we explored the correlation of CPA with transient elas-
tography values in a consecutive contemporary cohort of patients
with available measurements (n = 76): CPA, both at SM and HM, sig-
nificantly correlated with liver stiffness (P < 0.001 for both correla-
tions), with HM CPA having a significantly stronger correlation than
TABLE 1 Baseline characteristics of the 437 patients with biopsy‐proven NAFLD included in the study
Variable UK (286) Sweden (118) Greece (33) P* Total (437)
Age (y) 49 ± 13 57 ± 12 57 ± 13 <0.0001 51 ± 13
Caucasian ethnicitya, n (%) 171 (60) 118 (100) 33 (100) <0.00001 322 (74)
Females, n (%) 114 (40) 42 (36) 17 (52) 0.25 173 (39.6)
BMI (Kg/m2) 31.2 ± 5.8 29 ± 4.3 27.9 ± 4 0.003 30.2 ± 5.4
Hypertension, n (%) 104 (36) 103 (87) 25 (76) <0.0001 232 (53)
Dyslipidemia, n (%) 199 (70) 46 (39) 18 (55) <0.0001 263 (60.2)
Diabetes, n (%) 91 (32) 56 (47.5) 20 (61) <0.0001 167 (38.2)
CVD, n (%) 21 (7.3) 24 (20) 1 (3) <0.0001 46 (10.5)
NASH, n (%) 100 (35) 50 (42) 20 (61) 0.355 170 (39)
F0, n (%) 161 (56) 55 (47) 17 (52) 0.08 233 (53)
F1, n (%) 53 (18.5) 36 (30) 6 (18) 0.008 95 (22)
F2, n (%) 21 (7.5) 13 (11) 3 (9) 0.23 37 (8)
F3, n (%) 16 (6) 12 (10) 6 (18) 0.1 34 (8)
F4, n (%) 35 (12) 2 (2) 1 (3) 0.001 38 (9)
Platelets (x 10^9/L) 238 (85) 230 (76) 229 (93) 0.29 235 (84)
ALT (U/L) 62 (56) 60 (49) 49 (69) 0.67 60 (55)
AST (U/L) 41 (29) 36 (18) 38 (29) 0.08 39 (25)
Bilirubin (μmol/L) 11 (7) 11 (5) 13 (8) 0.13 11 (7)
Albumin (g/dL) 4.6 (0.4) 4.1 (0.4) 4.5 (0.5) <0.0001 4.5 (0.6)
INR 1 (0.1) 0.9 (0.1) 1 (0.2) <0.0001 1 (0.1)
CH (mmol/L) 5.3 (1.7) 5.6 (1.8) 5.4 (2.1) 0.45 5.4 (1.9)
HDL (mmol/L) 1.2 (0.4) 1.2 (0.3) 1.2 (0.4) 0.35 1.2 (0.4)
LDL (mmol/L) 2.9 (1.6) 3 (1.5) 3.3 (1.2) 0.46 3 (1.5)
TG (mmol/L) 1.8 (1.5) 1.7 (1.1) 1.3 (1) 0.37 1.7 (1.3)
Glucose (mmol/L) 5.4 (2) 6.2 (2.3) 5.8 (1.5) 0.001 5.6 (2.6)
HbA1c (mmol/mol) 39.9 (12) 27.9 (16) 39 (21) <0.001 37.7 (17)
Ferritin (pmol/L) 196 (289) 143 (152) 75 (181) 0.046 164.5 (234)
Values are reported as number (percentages) for qualitative variables, number ± SD or number (IQR) for quantitative variables.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CH, total cholesterol; CVD, cardiovascular disease; HbA1c, gly-
cosylated haemoglobin; HD, hepatic decompensation; HDL, high‐density lipoprotein; INR, international normalised ratio; LDL, low‐density lipoprotein;
NASH, non‐alcoholic steatohepatitis; TG, triglyceride.
aThe British cohort included other ethnicities as follows: Asian/Asian British (n = 43), Black/Caribbean/Black British (n = 13), Mixed (n = 4) or unknown
(n = 55).
*P value refers to the comparison between the Swedish and British cohorts.
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SM CPA (r = 0.73 vs. 0.68, P = 0.03, Figure 2A,B). Moreover, CPA
correlated well with both FIB‐4 (r = 0.47, P < 0.0001) and NAFLD
fibrosis score (r = 0.26, P < 0.0001) in the whole cohort of 437
patients.
3.4 | CPA and clinical outcomes
In Cox regression analysis, after correction for recruiting centre, age
at baseline (HR: 1.04, 95% CI: 1.01‐1.08), HM CPA (HR: 1.04, 95%
CI: 1.01‐1.08) and presence of advanced fibrosis (HR: 15.4, 95% CI:
5.02‐47.84) were independently associated with the combined out-
come (Table 3). In a competing risk Cox regression analysis, where
mortality from nonliver related aetiology was considered a compet-
ing risk, HM CPA (HR: 1.04, 95% CI: 1.001‐1.08) and advanced
fibrosis (HR: 9.55, 95% CI: 3.15 ‐ 28.9) but not age were still inde-
pendently associated with liver‐related events (Table 3). When the
analysis was repeated using SM CPA instead of HM CPA, age at
baseline (HR: 1.04, 95% CI: 1.01‐1.09), SM CPA (HR: 1.05, 95% CI:
1.02‐1.09) and presence of advanced fibrosis (HR: 13, 95% CI: 4.25‐
39.5) were the independently associated variables (Supplementary
Material, Table 1 Supplementary material Data S1). SM CPA and
advanced fibrosis remained independent predictors of liver‐related
events in the competing risk Cox regression analysis (Supplementary
Material, Table 1). In the subgroup of patients with advanced fibrosis
(n = 72), SM CPA (HR: 1.05, 95% CI: 1.01‐1.08, P = 0.005) was the
only independent predictor of liver related decompensation or death.
Figure 3 shows the AUROCs of HM CPA (0.79), advanced fibro-
sis (0.81), age at biopsy (0.70) and the model obtained by combining
the three parameters. The combined model had an AUROC of 0.87,
therefore showed a better accuracy at predicting hepatic decompen-
sation and/or liver‐related death than independent parameters.
The associated HM CPA cut‐off that best predicted the clinical
outcome of interest was 7.6% (sensitivity 87%, specificity 62%),
while the SM CPA cut‐off was 9.0% (sensitivity 70%, specificity
84%). Of the eight patients with fibrosis stage lower than F3 who
decompensated, five had a HM CPA value higher than 7.6 and all of
them had a HM CPA value lower than the CPA cut‐off for presence
of advanced fibrosis (>10.4%).
4 | DISCUSSION
In this study, we describe for the first time an accurate method for
the quantitative assessment of fibrosis in patients with NAFLD using
CPA with a higher magnification than that conventionally used in
chronic viral hepatitis. We further show that CPA is an independent
predictor of hepatic decompensation in such patients and could thus
be potentially used as a surrogate efficacy endpoint in clinical trials.
Therefore, CPA is a useful additional assessment to the standard
histopathological evaluation.
TABLE 2 Differences between SM and HM CPA according to
fibrosis stage
F0 F1 F2 F3 F4
HM CPA 5.4 (3.9) 6.6 (4.5) 8.6 (5.2) 11.2 (9.5) 23 (16)
SM CPA 3.4 (2.6) 4.1 (3.2) 6.2 (5.6) 10.7 (9.3) 21.3 (17)
P <0.0001 <0.0001 0.002 0.003 0.06
Values are reported as median (IQR).




F IGURE 1 Images taken at standard (A)
and high (B) magnification of liver sample
with fibrosis stage = F2 according to Brunt
et al system. The respective SM and HM
CPA measurement is 7.7 (A) and 14 (B)
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CPA was originally developed in patients with post‐transplant
HCV recurrence and showed good correlation with both HVPG and
clinical outcomes.10–12,18 We have previously demonstrated that
CPA can sub‐classify compensated cirrhosis better than the Laennec
system, as it is independently associated with clinical decompensa-
tion over and above the MELD score.9 However, CPA has not been
sufficiently tested in patients with nonviral disease aetiologies, par-
ticularly in the pre‐cirrhotic fibrosis stages. This is especially relevant
in patients with NAFLD and alcohol‐related liver disease, as these
patients develop pericellular and perisinusoidal fibrosis starting from
the centrilobular area with subsequent expansion towards the portal
tract.19 In contrast, development of fibrosis in viral hepatitis is ini-
tially centred around the portal tract with subsequent rapid
expansion towards the centrilobular vein.19 Existing studies on CPA
measurement in NAFLD did not test higher magnifications and
importantly did not validate CPA against clinical outcomes.20,21 We
therefore tested different magnifications for digital analysis and CPA
measurement in order to accurately quantify the presence of fine
pericellular fibrosis that could be missed at a standard magnification.
Our results convincingly show that an objective magnification of ×4
is far more accurate in measuring fibrosis in pre‐cirrhotic patients,
with values up to 100% higher than when using the conventional
magnification. Increasing the magnification to ×10 did not substan-
tially change the accuracy of the method. In addition, our data
demonstrate that ×4 magnification measurements have a better cor-

































F IGURE 2 (A) Correlation between HM
CPA and liver stiffness (LS) measured by
transient elastography (r = 0.73). (B)
Correlation between SM CPA and liver
stiffness (LS) measured by transient
elastography (r = 0.68)
TABLE 3 Predictors of hepatic decompensation and/or liver‐related mortality at the Cox regression univariate, multivariate and multivariate
competing risk analysis
Variable





Competing risks: nonliver related
deaths
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Cohorta NS
Swedish 0.77 (0.34‐1.72) 0.52
Greek 1.17 (0.27‐5.05) 0.83
Sex 0.96 (0.47‐1.97) 0.91
BMI 1.10 (1.04‐1.17) 0.001 NS
Age at biopsy 1.06 (1.03‐1.09) <0.0001 1.04 (1.01‐1.08) 0.03
Diabetes 3.93 (1.82‐8.50) 0.001 NS
Hypertension 1.8 (0.85‐3.81) 0.12
Dyslipidemia 0.72 (0.35‐1.45) 0.38
HM CPA 1.11 (1.08‐1.13) <0.0001 1.04 (1.01‐1.08) 0.04 1.04 (1.001‐1.08) 0.04
SM CPA 1.11 (1.08‐1.13) <0.0001
≥F3 37.9(14.1‐101) <0.0001 15.4 (5.02‐47.84) <0.0001 9.55 (3.15‐28.9) <0.0001
NASH 6.94 (3.06‐15.72) <0.0001 NS
Bilirubin 1.02 (1‐1.04) 0.06 NS
ALT 0.99 (0.98‐1.01) 0.43
AST 1.003 (0.99‐1.01) 0.29
≥F3, advanced fibrosis; ALT, alanine aminotransferase; AST, aspartate aminotransferase.; BMI, body mass index; HM CPA, high magnification collagen
proportionate area; HR, Hazards Ration; NASH, non‐alcoholic steatohepatitis; SM CPA, standard magnification collagen proportionate area.
aCompared to the British cohort.
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therefore propose that the ×4 magnification should be the standard
procedure of quantifying fibrosis with CPA in NAFLD, particularly in
stages F0‐F2.
Furthermore, this study demonstrates that CPA, along with
advanced fibrosis, is an independent risk factor for liver‐related
decompensation and death. This result was obtained by investigating
a cohort of 437 patients with longitudinal follow‐up, the majority of
whom (n = 319) had not been previously described in cohort studies.
Such findings were also confirmed in a competing risk analysis,
where non‐liver related deaths were counted as competing risks.
Moreover, in the subset of patients with advanced fibrosis, CPA was
the only independent risk factor associated with liver‐related out-
comes. Interestingly, the NAS was not associated with such events,
in accordance with recent results from European23 and American24
cohorts. These observations not only confirm that fibrosis is the
effective key driver of liver‐related complications in NAFLD, but also
highlight the need of making the assessment of fibrosis a central ele-
ment in the design and interpretation of current clinical trials.
NAFLD is currently labelled as a disease of an unmet clinical
need and potential treatments are in an accelerated pathway for
FDA approval.25 Therefore, a pharmaceutical treatment will be
licensed based on the effect on surrogate outcomes, while the com-
pany will have to provide further post‐licensing evidence of efficacy
on hard clinical endpoints. Current surrogate endpoints include a
combination of improvement or resolution of NASH based on the
NAS score with no worsening of fibrosis or improvement of fibrosis
with no worsening of NASH.25 The NAS score is a problematic
endpoint, given its high inter and intra‐observer variability, its heavy
reliance on steatosis, the exclusion of portal inflammation and the
poor correlation with clinical outcomes.16,23,24 Although it is indis-
putable that inflammation (loosely termed as steatohepatitis) is one
of the key drivers of the fibrogenic process, it is not easy to quantify
and characterise in its multicellular complexity.26 Therefore, the
extent of fibrotic transformation constitutes the hard end‐point of
this pathophysiological process. Fibrosis is currently measured semi‐
quantitatively, using a score with a scale of 0 to 4 that takes into
account both architectural changes and fibrosis.27 Assigned scores
are overall simple descriptors and do not have a quantitative relation
with each other, as also confirmed in the present study. Therefore,
progression or regression through stages might not be observed in
the relative short duration of trials, while subtle changes in fibrosis
might be missed. These shortcomings might provide false assurances
or even “false negative” signals for further development of treat-
ments.28 In that sense, CPA can provide a refinement of fibrosis
assessment and is an ideal candidate to explore as a surrogate out-
come in trials in combination with “conventional” histopathological
staging. Further research is required to understand what magnitude
of CPA changes is clinically relevant.
Surrogate outcomes should be able to predict an intervention's
effect on a clinically meaningful outcome.29 CPA is independently
associated with liver‐related events and is a purely quantitative mea-
sure and therefore can offer supplementary information to the semi‐
quantitative fibrosis stage. It is also biologically plausible that
improvement of CPA following therapeutic intervention will translate
in a delay in the appearance of clinical events, although this will
require further validation. In terms of accuracy, CPA measurements
have a high inter‐ and intra‐observer agreement (k consistently
greater than 0.9), are inexpensive once the necessary equipment and
software is purchased and are not time consuming. We have previ-
ously shown that sampling variability does not influence this assess-
ment in cirrhosis, as measurements from the left and right liver lobe
of explanted livers show similar amounts of fibrosis.30 Moreover, rel-
atively accurate measurements can be obtained from biopsy samples
as small as 5 mm.31,32
Lastly, CPA correlated well with liver stiffness as measured by
transient elastography. Quantitative non‐invasive fibrosis tests are
better validated against a pure quantitative measure of fibrosis
rather than the semi‐quantitative fibrosis stages.33 This strategy will
allow a more targeted approach to liver fibrosis and will also bypass
limitations of the traditional staging, such as sampling and inter‐ob-
server variability but also the ceiling of cirrhosis with no further abil-
ity of sub‐classification.
This is a retrospective study with obvious limitations, including
reliance on medical records, absence of a standardised protocol for
follow‐up and most likely a selection bias for patients at greater risk
of progression. Nevertheless, we included consecutive patients
across three different countries with different characteristics and a
long follow‐up and have been able to ascertain the final outcomes.
In conclusion, we described an accurate way of quantifying fibro-





















F IGURE 3 Comparative areas under the ROC (AUROCs) of
quantitative and semi‐quantitative predictors of mortality for liver
related events (death or clinical decompensation) in patients with
biopsy‐proven NAFLD. AUROCs are: HM CPA = 0.79 (95% CI: 0.75‐
0.83); advanced fibrosis = 0.81 (95% CI: 0.76‐0.89); age at
biopsy = 0.70 (95% CI: 0.65‐0.74), combination of the three
variables (combined variable): 0.87 (95% CI: 0.83‐0.90)
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this is independently associated with clinical outcomes. Our findings
support the routine measurement of CPA in combination with the
standard histopathological evaluation in liver biopsies of patients
with NAFLD, as it provides additional information to the traditional
semi‐quantitative staging. More importantly, they suggest the explo-
ration of HM CPA as a surrogate endpoint in clinical trials of
patients with NASH.
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